[
    [
        {
            "time": "",
            "original_text": "半年报数据显示：复星、中国医药营收达百亿，科伦净利迅增，泰格研发投入超销售费用",
            "features": {
                "keywords": [
                    "半年报",
                    "复星",
                    "中国医药",
                    "科伦",
                    "泰格",
                    "营收",
                    "净利",
                    "研发投入"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "半年报数据显示：复星、中国医药营收达百亿，科伦净利迅增，泰格研发投入超销售费用",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：理性看待药监人事变化 积极布局估值切换行情",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "药监",
                    "人事变化",
                    "估值切换"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：理性看待药监人事变化 积极布局估值切换行情",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【西南医药朱国广团队】同仁堂（600085）业绩增长稳定，发展潜力巨大",
            "features": {
                "keywords": [
                    "西南医药",
                    "同仁堂",
                    "业绩增长",
                    "发展潜力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【西南医药朱国广团队】同仁堂（600085）业绩增长稳定，发展潜力巨大",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级] 同仁堂(600085)中报点评：业绩符合预期 “品牌+品种”铸就护城河",
            "features": {
                "keywords": [
                    "同仁堂",
                    "中报",
                    "业绩",
                    "品牌",
                    "品种",
                    "护城河"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[推荐评级] 同仁堂(600085)中报点评：业绩符合预期 “品牌+品种”铸就护城河",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "中证报头版：青睐制造业、偏爱大蓝筹，机构二季度布局路径隐现",
            "features": {
                "keywords": [
                    "中证报",
                    "制造业",
                    "大蓝筹",
                    "机构",
                    "二季度",
                    "布局路径"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "制造业",
                    "蓝筹股"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中证报头版：青睐制造业、偏爱大蓝筹，机构二季度布局路径隐现",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "证金二季度增持两公司 华大基因等公司披露分配预案",
            "features": {
                "keywords": [
                    "证金",
                    "二季度",
                    "增持",
                    "华大基因",
                    "分配预案"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "证金二季度增持两公司 华大基因等公司披露分配预案",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]